世界の原発性胆汁性胆管炎(PBC)治療薬市場(2024年~2028年)

◆英語タイトル:Global Primary Biliary Cholangitis Therapeutics Market 2024-2028

Technavioが発行した調査報告書(IRTNTR76783-24)◆商品コード:IRTNTR76783-24
◆発行会社(リサーチ会社):Technavio
◆発行日:2023年11月9日
◆ページ数:約120
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥380,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥608,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

原発性胆汁性胆管炎(PBC)治療薬の世界市場 2024-2028原発性胆汁性胆管炎(PBC)治療薬市場は2023-2028年に3億4,685万米ドル成長し、予測期間中のCAGRは8.75%で加速すると予測されます。この調査レポートは、原発性胆汁性胆管炎(PBC)治療薬市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題、約25のベンダーを網羅したベンダー分析などを掲載しています。
現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場を牽引するのは、遠隔医療と遠隔モニタリングの台頭、医療業界における投資と開発の増加、原発性胆汁性胆管炎(PBC)治療薬市場における製品上市の増加などです。

Technavio社の原発性胆汁性胆管炎(PBC)治療薬市場は以下のようにセグメント分けされています:
タイプ別
- 一次治療薬
- 二次治療薬

流通チャネル別
- ドラッグストアおよび小売薬局
- 病院薬局
- オンライン薬局

地域別
- 北米
- ヨーロッパ
- アジア
- その他の地域(ROW)

本調査では、今後数年間の原発性胆汁性胆管炎(PBC)治療薬市場の成長を促進する主な理由の1つとして、政府の医療費支出による研究開発需要の増加を挙げています。また、高齢者人口の増加や、メーカーによる原発性胆汁性胆管炎(PBC)治療薬への研究開発投資の増加は、市場の大きな需要につながるでしょう。

この調査レポートは、原発性胆汁性胆管炎(PBC)治療薬市場を調査・分析し、以下の刊行物を出版しています:
- 原発性胆汁性胆管炎(PBC)治療薬市場の規模
- 原発性胆汁性胆管炎(PBC)治療薬市場予測
- 原発性胆汁性胆管炎(PBC)治療薬市場の産業分析

堅牢なベンダー分析は、顧客が市場での地位を向上させるのに役立つように設計されており、これに沿って、本レポートは、Abbott Laboratories, AbbVie Inc., Alkem Laboratories Ltd., Eli Lilly and Co., GENFIT SA, Glenmark Pharmaceuticals Ltd., ICE S.p.a., Intercept Pharmaceuticals Inc., Ipsen Pharma, Leeford Healthcare Ltd., NGM Biopharmaceuticals Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd.などを分析しています。また、原発性胆汁性胆管炎(PBC)治療薬市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。当レポートでは、主要ベンダーの分析に加え、包括的な市場とベンダーの状況を掲載しています。

当出版社は、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、総括する方法で、市場の詳細な姿を提示しています。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

1 エグゼクティブサマリー
2 市場概況
3 市場規模
4 過去の市場規模
5 ファイブフォース分析
6 世界の原発性胆汁性胆管炎(PBC)治療薬市場規模:種類別分析
7 世界の原発性胆汁性胆管炎(PBC)治療薬市場規模:流通チャネル別分析
8 顧客状況
9 地域別状況
10 推進要因・課題・動向
11 企業状況
12 企業分析
13 付録

❖ レポートの目次 ❖

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 14: Chart on Global – Market size and forecast 2023-2028 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2023-2028 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• 4 Historic Market Size
o 4.1 Global primary biliary cholangitis therapeutics market 2018 – 2022
o Exhibit 18: Historic Market Size – Data Table on global primary biliary cholangitis therapeutics market 2018 – 2022 ($ million)
o 4.2 Type Segment Analysis 2018 – 2022
o Exhibit 19: Historic Market Size – Type Segment 2018 – 2022 ($ million)
o 4.3 Distribution Channel Segment Analysis 2018 – 2022
o Exhibit 20: Historic Market Size – Distribution Channel Segment 2018 – 2022 ($ million)
o 4.4 Geography Segment Analysis 2018 – 2022
o Exhibit 21: Historic Market Size – Geography Segment 2018 – 2022 ($ million)
o 4.5 Country Segment Analysis 2018 – 2022
o Exhibit 22: Historic Market Size – Country Segment 2018 – 2022 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2023 and 2028
• 6 Market Segmentation by Type
o 6.1 Market segments
o Exhibit 30: Chart on Type – Market share 2023-2028 (%)
o Exhibit 31: Data Table on Type – Market share 2023-2028 (%)
o 6.2 Comparison by Type
o Exhibit 32: Chart on Comparison by Type
o Exhibit 33: Data Table on Comparison by Type
o 6.3 Primary drug – Market size and forecast 2023-2028
o Exhibit 34: Chart on Primary drug – Market size and forecast 2023-2028 ($ million)
o Exhibit 35: Data Table on Primary drug – Market size and forecast 2023-2028 ($ million)
o Exhibit 36: Chart on Primary drug – Year-over-year growth 2023-2028 (%)
o Exhibit 37: Data Table on Primary drug – Year-over-year growth 2023-2028 (%)
o 6.4 Secondary drug – Market size and forecast 2023-2028
o Exhibit 38: Chart on Secondary drug – Market size and forecast 2023-2028 ($ million)
o Exhibit 39: Data Table on Secondary drug – Market size and forecast 2023-2028 ($ million)
o Exhibit 40: Chart on Secondary drug – Year-over-year growth 2023-2028 (%)
o Exhibit 41: Data Table on Secondary drug – Year-over-year growth 2023-2028 (%)
o 6.5 Market opportunity by Type
o Exhibit 42: Market opportunity by Type ($ million)
o Exhibit 43: Data Table on Market opportunity by Type ($ million)
• 7 Market Segmentation by Distribution Channel
o 7.1 Market segments
o Exhibit 44: Chart on Distribution Channel – Market share 2023-2028 (%)
o Exhibit 45: Data Table on Distribution Channel – Market share 2023-2028 (%)
o 7.2 Comparison by Distribution Channel
o Exhibit 46: Chart on Comparison by Distribution Channel
o Exhibit 47: Data Table on Comparison by Distribution Channel
o 7.3 Drug stores and retail pharmacies – Market size and forecast 2023-2028
o Exhibit 48: Chart on Drug stores and retail pharmacies – Market size and forecast 2023-2028 ($ million)
o Exhibit 49: Data Table on Drug stores and retail pharmacies – Market size and forecast 2023-2028 ($ million)
o Exhibit 50: Chart on Drug stores and retail pharmacies – Year-over-year growth 2023-2028 (%)
o Exhibit 51: Data Table on Drug stores and retail pharmacies – Year-over-year growth 2023-2028 (%)
o 7.4 Hospital pharmacies – Market size and forecast 2023-2028
o Exhibit 52: Chart on Hospital pharmacies – Market size and forecast 2023-2028 ($ million)
o Exhibit 53: Data Table on Hospital pharmacies – Market size and forecast 2023-2028 ($ million)
o Exhibit 54: Chart on Hospital pharmacies – Year-over-year growth 2023-2028 (%)
o Exhibit 55: Data Table on Hospital pharmacies – Year-over-year growth 2023-2028 (%)
o 7.5 Online pharmacies – Market size and forecast 2023-2028
o Exhibit 56: Chart on Online pharmacies – Market size and forecast 2023-2028 ($ million)
o Exhibit 57: Data Table on Online pharmacies – Market size and forecast 2023-2028 ($ million)
o Exhibit 58: Chart on Online pharmacies – Year-over-year growth 2023-2028 (%)
o Exhibit 59: Data Table on Online pharmacies – Year-over-year growth 2023-2028 (%)
o 7.6 Market opportunity by Distribution Channel
o Exhibit 60: Market opportunity by Distribution Channel ($ million)
o Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
o Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
o 9.2 Geographic comparison
o Exhibit 65: Chart on Geographic comparison
o Exhibit 66: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2023-2028
o Exhibit 67: Chart on North America – Market size and forecast 2023-2028 ($ million)
o Exhibit 68: Data Table on North America – Market size and forecast 2023-2028 ($ million)
o Exhibit 69: Chart on North America – Year-over-year growth 2023-2028 (%)
o Exhibit 70: Data Table on North America – Year-over-year growth 2023-2028 (%)
o 9.4 Europe – Market size and forecast 2023-2028
o Exhibit 71: Chart on Europe – Market size and forecast 2023-2028 ($ million)
o Exhibit 72: Data Table on Europe – Market size and forecast 2023-2028 ($ million)
o Exhibit 73: Chart on Europe – Year-over-year growth 2023-2028 (%)
o Exhibit 74: Data Table on Europe – Year-over-year growth 2023-2028 (%)
o 9.5 Asia – Market size and forecast 2023-2028
o Exhibit 75: Chart on Asia – Market size and forecast 2023-2028 ($ million)
o Exhibit 76: Data Table on Asia – Market size and forecast 2023-2028 ($ million)
o Exhibit 77: Chart on Asia – Year-over-year growth 2023-2028 (%)
o Exhibit 78: Data Table on Asia – Year-over-year growth 2023-2028 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2023-2028
o Exhibit 79: Chart on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
o Exhibit 80: Data Table on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
o Exhibit 81: Chart on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
o Exhibit 82: Data Table on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
o 9.7 US – Market size and forecast 2023-2028
o Exhibit 83: Chart on US – Market size and forecast 2023-2028 ($ million)
o Exhibit 84: Data Table on US – Market size and forecast 2023-2028 ($ million)
o Exhibit 85: Chart on US – Year-over-year growth 2023-2028 (%)
o Exhibit 86: Data Table on US – Year-over-year growth 2023-2028 (%)
o 9.8 Canada – Market size and forecast 2023-2028
o Exhibit 87: Chart on Canada – Market size and forecast 2023-2028 ($ million)
o Exhibit 88: Data Table on Canada – Market size and forecast 2023-2028 ($ million)
o Exhibit 89: Chart on Canada – Year-over-year growth 2023-2028 (%)
o Exhibit 90: Data Table on Canada – Year-over-year growth 2023-2028 (%)
o 9.9 Germany – Market size and forecast 2023-2028
o Exhibit 91: Chart on Germany – Market size and forecast 2023-2028 ($ million)
o Exhibit 92: Data Table on Germany – Market size and forecast 2023-2028 ($ million)
o Exhibit 93: Chart on Germany – Year-over-year growth 2023-2028 (%)
o Exhibit 94: Data Table on Germany – Year-over-year growth 2023-2028 (%)
o 9.10 China – Market size and forecast 2023-2028
o Exhibit 95: Chart on China – Market size and forecast 2023-2028 ($ million)
o Exhibit 96: Data Table on China – Market size and forecast 2023-2028 ($ million)
o Exhibit 97: Chart on China – Year-over-year growth 2023-2028 (%)
o Exhibit 98: Data Table on China – Year-over-year growth 2023-2028 (%)
o 9.11 UK – Market size and forecast 2023-2028
o Exhibit 99: Chart on UK – Market size and forecast 2023-2028 ($ million)
o Exhibit 100: Data Table on UK – Market size and forecast 2023-2028 ($ million)
o Exhibit 101: Chart on UK – Year-over-year growth 2023-2028 (%)
o Exhibit 102: Data Table on UK – Year-over-year growth 2023-2028 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 103: Market opportunity By Geographical Landscape ($ million)
o Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 105: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 107: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 108: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 109: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 110: Matrix on vendor position and classification
o 12.3 Abbott Laboratories
o Exhibit 111: Abbott Laboratories – Overview
o Exhibit 112: Abbott Laboratories – Business segments
o Exhibit 113: Abbott Laboratories – Key news
o Exhibit 114: Abbott Laboratories – Key offerings
o Exhibit 115: Abbott Laboratories – Segment focus
o 12.4 AbbVie Inc.
o Exhibit 116: AbbVie Inc. – Overview
o Exhibit 117: AbbVie Inc. – Product / Service
o Exhibit 118: AbbVie Inc. – Key news
o Exhibit 119: AbbVie Inc. – Key offerings
o 12.5 Alkem Laboratories Ltd.
o Exhibit 120: Alkem Laboratories Ltd. – Overview
o Exhibit 121: Alkem Laboratories Ltd. – Business segments
o Exhibit 122: Alkem Laboratories Ltd. – Key news
o Exhibit 123: Alkem Laboratories Ltd. – Key offerings
o Exhibit 124: Alkem Laboratories Ltd. – Segment focus
o 12.6 Eli Lilly and Co.
o Exhibit 125: Eli Lilly and Co. – Overview
o Exhibit 126: Eli Lilly and Co. – Product / Service
o Exhibit 127: Eli Lilly and Co. – Key news
o Exhibit 128: Eli Lilly and Co. – Key offerings
o 12.7 GENFIT SA
o Exhibit 129: GENFIT SA – Overview
o Exhibit 130: GENFIT SA – Product / Service
o Exhibit 131: GENFIT SA – Key offerings
o 12.8 Glenmark Pharmaceuticals Ltd.
o Exhibit 132: Glenmark Pharmaceuticals Ltd. – Overview
o Exhibit 133: Glenmark Pharmaceuticals Ltd. – Product / Service
o Exhibit 134: Glenmark Pharmaceuticals Ltd. – Key offerings
o 12.9 ICE S.p.a.
o Exhibit 135: ICE S.p.a. – Overview
o Exhibit 136: ICE S.p.a. – Product / Service
o Exhibit 137: ICE S.p.a. – Key offerings
o 12.10 Intercept Pharmaceuticals Inc.
o Exhibit 138: Intercept Pharmaceuticals Inc. – Overview
o Exhibit 139: Intercept Pharmaceuticals Inc. – Product / Service
o Exhibit 140: Intercept Pharmaceuticals Inc. – Key offerings
o 12.11 Ipsen Pharma
o Exhibit 141: Ipsen Pharma – Overview
o Exhibit 142: Ipsen Pharma – Business segments
o Exhibit 143: Ipsen Pharma – Key offerings
o Exhibit 144: Ipsen Pharma – Segment focus
o 12.12 Leeford Healthcare Ltd.
o Exhibit 145: Leeford Healthcare Ltd. – Overview
o Exhibit 146: Leeford Healthcare Ltd. – Key offerings
o 12.13 NGM Biopharmaceuticals Inc.
o Exhibit 147: NGM Biopharmaceuticals Inc. – Overview
o Exhibit 148: NGM Biopharmaceuticals Inc. – Key offerings
o 12.14 Novartis AG
o Exhibit 149: Novartis AG – Overview
o Exhibit 150: Novartis AG – Business segments
o Exhibit 151: Novartis AG – Key offerings
o Exhibit 152: Novartis AG – Segment focus
o 12.15 Teva Pharmaceutical Industries Ltd.
o Exhibit 153: Teva Pharmaceutical Industries Ltd. – Overview
o Exhibit 154: Teva Pharmaceutical Industries Ltd. – Business segments
o Exhibit 155: Teva Pharmaceutical Industries Ltd. – Key news
o Exhibit 156: Teva Pharmaceutical Industries Ltd. – Key offerings
o Exhibit 157: Teva Pharmaceutical Industries Ltd. – Segment focus
o 12.16 Viatris Inc.
o Exhibit 158: Viatris Inc. – Overview
o Exhibit 159: Viatris Inc. – Business segments
o Exhibit 160: Viatris Inc. – Key news
o Exhibit 161: Viatris Inc. – Key offerings
o Exhibit 162: Viatris Inc. – Segment focus
o 12.17 Zydus Lifesciences Ltd.
o Exhibit 163: Zydus Lifesciences Ltd. – Overview
o Exhibit 164: Zydus Lifesciences Ltd. – Business segments
o Exhibit 165: Zydus Lifesciences Ltd. – Key offerings
o Exhibit 166: Zydus Lifesciences Ltd. – Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 167: Inclusions checklist
o Exhibit 168: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 169: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 170: Research methodology
o Exhibit 171: Validation techniques employed for market sizing
o Exhibit 172: Information sources
o 13.5 List of abbreviations
o Exhibit 173: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Type
Exhibits6: Executive Summary – Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2023-2028 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2023-2028 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits18: Historic Market Size – Data Table on global primary biliary cholangitis therapeutics market 2018 – 2022 ($ million)
Exhibits19: Historic Market Size – Type Segment 2018 – 2022 ($ million)
Exhibits20: Historic Market Size – Distribution Channel Segment 2018 – 2022 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2018 – 2022 ($ million)
Exhibits22: Historic Market Size – Country Segment 2018 – 2022 ($ million)
Exhibits23: Five forces analysis – Comparison between 2023 and 2028
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
Exhibits26: Threat of new entrants – Impact of key factors in 2023 and 2028
Exhibits27: Threat of substitutes – Impact of key factors in 2023 and 2028
Exhibits28: Threat of rivalry – Impact of key factors in 2023 and 2028
Exhibits29: Chart on Market condition – Five forces 2023 and 2028
Exhibits30: Chart on Type – Market share 2023-2028 (%)
Exhibits31: Data Table on Type – Market share 2023-2028 (%)
Exhibits32: Chart on Comparison by Type
Exhibits33: Data Table on Comparison by Type
Exhibits34: Chart on Primary drug – Market size and forecast 2023-2028 ($ million)
Exhibits35: Data Table on Primary drug – Market size and forecast 2023-2028 ($ million)
Exhibits36: Chart on Primary drug – Year-over-year growth 2023-2028 (%)
Exhibits37: Data Table on Primary drug – Year-over-year growth 2023-2028 (%)
Exhibits38: Chart on Secondary drug – Market size and forecast 2023-2028 ($ million)
Exhibits39: Data Table on Secondary drug – Market size and forecast 2023-2028 ($ million)
Exhibits40: Chart on Secondary drug – Year-over-year growth 2023-2028 (%)
Exhibits41: Data Table on Secondary drug – Year-over-year growth 2023-2028 (%)
Exhibits42: Market opportunity by Type ($ million)
Exhibits43: Data Table on Market opportunity by Type ($ million)
Exhibits44: Chart on Distribution Channel – Market share 2023-2028 (%)
Exhibits45: Data Table on Distribution Channel – Market share 2023-2028 (%)
Exhibits46: Chart on Comparison by Distribution Channel
Exhibits47: Data Table on Comparison by Distribution Channel
Exhibits48: Chart on Drug stores and retail pharmacies – Market size and forecast 2023-2028 ($ million)
Exhibits49: Data Table on Drug stores and retail pharmacies – Market size and forecast 2023-2028 ($ million)
Exhibits50: Chart on Drug stores and retail pharmacies – Year-over-year growth 2023-2028 (%)
Exhibits51: Data Table on Drug stores and retail pharmacies – Year-over-year growth 2023-2028 (%)
Exhibits52: Chart on Hospital pharmacies – Market size and forecast 2023-2028 ($ million)
Exhibits53: Data Table on Hospital pharmacies – Market size and forecast 2023-2028 ($ million)
Exhibits54: Chart on Hospital pharmacies – Year-over-year growth 2023-2028 (%)
Exhibits55: Data Table on Hospital pharmacies – Year-over-year growth 2023-2028 (%)
Exhibits56: Chart on Online pharmacies – Market size and forecast 2023-2028 ($ million)
Exhibits57: Data Table on Online pharmacies – Market size and forecast 2023-2028 ($ million)
Exhibits58: Chart on Online pharmacies – Year-over-year growth 2023-2028 (%)
Exhibits59: Data Table on Online pharmacies – Year-over-year growth 2023-2028 (%)
Exhibits60: Market opportunity by Distribution Channel ($ million)
Exhibits61: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits65: Chart on Geographic comparison
Exhibits66: Data Table on Geographic comparison
Exhibits67: Chart on North America – Market size and forecast 2023-2028 ($ million)
Exhibits68: Data Table on North America – Market size and forecast 2023-2028 ($ million)
Exhibits69: Chart on North America – Year-over-year growth 2023-2028 (%)
Exhibits70: Data Table on North America – Year-over-year growth 2023-2028 (%)
Exhibits71: Chart on Europe – Market size and forecast 2023-2028 ($ million)
Exhibits72: Data Table on Europe – Market size and forecast 2023-2028 ($ million)
Exhibits73: Chart on Europe – Year-over-year growth 2023-2028 (%)
Exhibits74: Data Table on Europe – Year-over-year growth 2023-2028 (%)
Exhibits75: Chart on Asia – Market size and forecast 2023-2028 ($ million)
Exhibits76: Data Table on Asia – Market size and forecast 2023-2028 ($ million)
Exhibits77: Chart on Asia – Year-over-year growth 2023-2028 (%)
Exhibits78: Data Table on Asia – Year-over-year growth 2023-2028 (%)
Exhibits79: Chart on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
Exhibits80: Data Table on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
Exhibits81: Chart on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
Exhibits82: Data Table on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
Exhibits83: Chart on US – Market size and forecast 2023-2028 ($ million)
Exhibits84: Data Table on US – Market size and forecast 2023-2028 ($ million)
Exhibits85: Chart on US – Year-over-year growth 2023-2028 (%)
Exhibits86: Data Table on US – Year-over-year growth 2023-2028 (%)
Exhibits87: Chart on Canada – Market size and forecast 2023-2028 ($ million)
Exhibits88: Data Table on Canada – Market size and forecast 2023-2028 ($ million)
Exhibits89: Chart on Canada – Year-over-year growth 2023-2028 (%)
Exhibits90: Data Table on Canada – Year-over-year growth 2023-2028 (%)
Exhibits91: Chart on Germany – Market size and forecast 2023-2028 ($ million)
Exhibits92: Data Table on Germany – Market size and forecast 2023-2028 ($ million)
Exhibits93: Chart on Germany – Year-over-year growth 2023-2028 (%)
Exhibits94: Data Table on Germany – Year-over-year growth 2023-2028 (%)
Exhibits95: Chart on China – Market size and forecast 2023-2028 ($ million)
Exhibits96: Data Table on China – Market size and forecast 2023-2028 ($ million)
Exhibits97: Chart on China – Year-over-year growth 2023-2028 (%)
Exhibits98: Data Table on China – Year-over-year growth 2023-2028 (%)
Exhibits99: Chart on UK – Market size and forecast 2023-2028 ($ million)
Exhibits100: Data Table on UK – Market size and forecast 2023-2028 ($ million)
Exhibits101: Chart on UK – Year-over-year growth 2023-2028 (%)
Exhibits102: Data Table on UK – Year-over-year growth 2023-2028 (%)
Exhibits103: Market opportunity By Geographical Landscape ($ million)
Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits105: Impact of drivers and challenges in 2023 and 2028
Exhibits106: Overview on Criticality of inputs and Factors of differentiation
Exhibits107: Overview on factors of disruption
Exhibits108: Impact of key risks on business
Exhibits109: Vendors covered
Exhibits110: Matrix on vendor position and classification
Exhibits111: Abbott Laboratories – Overview
Exhibits112: Abbott Laboratories – Business segments
Exhibits113: Abbott Laboratories – Key news
Exhibits114: Abbott Laboratories – Key offerings
Exhibits115: Abbott Laboratories – Segment focus
Exhibits116: AbbVie Inc. – Overview
Exhibits117: AbbVie Inc. – Product / Service
Exhibits118: AbbVie Inc. – Key news
Exhibits119: AbbVie Inc. – Key offerings
Exhibits120: Alkem Laboratories Ltd. – Overview
Exhibits121: Alkem Laboratories Ltd. – Business segments
Exhibits122: Alkem Laboratories Ltd. – Key news
Exhibits123: Alkem Laboratories Ltd. – Key offerings
Exhibits124: Alkem Laboratories Ltd. – Segment focus
Exhibits125: Eli Lilly and Co. – Overview
Exhibits126: Eli Lilly and Co. – Product / Service
Exhibits127: Eli Lilly and Co. – Key news
Exhibits128: Eli Lilly and Co. – Key offerings
Exhibits129: GENFIT SA – Overview
Exhibits130: GENFIT SA – Product / Service
Exhibits131: GENFIT SA – Key offerings
Exhibits132: Glenmark Pharmaceuticals Ltd. – Overview
Exhibits133: Glenmark Pharmaceuticals Ltd. – Product / Service
Exhibits134: Glenmark Pharmaceuticals Ltd. – Key offerings
Exhibits135: ICE S.p.a. – Overview
Exhibits136: ICE S.p.a. – Product / Service
Exhibits137: ICE S.p.a. – Key offerings
Exhibits138: Intercept Pharmaceuticals Inc. – Overview
Exhibits139: Intercept Pharmaceuticals Inc. – Product / Service
Exhibits140: Intercept Pharmaceuticals Inc. – Key offerings
Exhibits141: Ipsen Pharma – Overview
Exhibits142: Ipsen Pharma – Business segments
Exhibits143: Ipsen Pharma – Key offerings
Exhibits144: Ipsen Pharma – Segment focus
Exhibits145: Leeford Healthcare Ltd. – Overview
Exhibits146: Leeford Healthcare Ltd. – Key offerings
Exhibits147: NGM Biopharmaceuticals Inc. – Overview
Exhibits148: NGM Biopharmaceuticals Inc. – Key offerings
Exhibits149: Novartis AG – Overview
Exhibits150: Novartis AG – Business segments
Exhibits151: Novartis AG – Key offerings
Exhibits152: Novartis AG – Segment focus
Exhibits153: Teva Pharmaceutical Industries Ltd. – Overview
Exhibits154: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibits155: Teva Pharmaceutical Industries Ltd. – Key news
Exhibits156: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibits157: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibits158: Viatris Inc. – Overview
Exhibits159: Viatris Inc. – Business segments
Exhibits160: Viatris Inc. – Key news
Exhibits161: Viatris Inc. – Key offerings
Exhibits162: Viatris Inc. – Segment focus
Exhibits163: Zydus Lifesciences Ltd. – Overview
Exhibits164: Zydus Lifesciences Ltd. – Business segments
Exhibits165: Zydus Lifesciences Ltd. – Key offerings
Exhibits166: Zydus Lifesciences Ltd. – Segment focus
Exhibits167: Inclusions checklist
Exhibits168: Exclusions checklist
Exhibits169: Currency conversion rates for US$
Exhibits170: Research methodology
Exhibits171: Validation techniques employed for market sizing
Exhibits172: Information sources
Exhibits173: List of abbreviations



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の原発性胆汁性胆管炎(PBC)治療薬市場(2024年~2028年)(Global Primary Biliary Cholangitis Therapeutics Market 2024-2028)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆